Outcome of Patients with ALK plus NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management

被引：0
|
作者：
De Petris, Luigi [1 ]
Friesland, Signe [1 ]
Brodin, Daniel [2 ]
Carstens, Hanna [1 ]
Falkenius, Johan [1 ]
Grundberg, Oscar [2 ]
Lofdahl, Magnus [2 ]
Helleday, Clara Lenneby [1 ]
Karimi, Reza [2 ]
Ojdahl-Boden, Anna [2 ]
Tsakonas, Georgios [1 ]
Ekman, Simon [1 ]
Kolbeck, Karl-Gustav [2 ]
机构：
[1] Karolinska Univ Hosp, Oncol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Resp Med & Allergol, Stockholm, Sweden
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
ALK; WBRT; CNS Metastasis; 2nd generation ALKi;
D O I：
10.1016/j.jtho.2016.11.1294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03b-013
引用
收藏
页码：S940 / S941
页数：2
相关论文
共 50 条
  • [31] Immunotherapy in NSCLC Patients with Brain Metastases
    Buriolla, Silvia
    Pelizzari, Giacomo
    Corvaja, Carla
    Alberti, Martina
    Targato, Giada
    Bortolot, Martina
    Torresan, Sara
    Cortiula, Francesco
    Fasola, Gianpiero
    Follador, Alessandro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [32] Symptoms of Bone and Liver Metastases in Patients with ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Guerin, Annie
    Sasane, Medha
    Nitulescu, Roy
    Zhang, Jie
    Culver, Kenneth W.
    Wu, Eric Q.
    Macalalad, Alexander R.
    Dalai, Anand
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [33] Role of radiotherapy in the management of brain metastases of NSCLC - Decision criteria in clinical routine
    Glatzer, Markus
    Faivre-Finn, Corinne
    De Ruysscher, Dirk
    Widder, Joachim
    Van Houtte, Paul
    Troost, Esther G. C.
    Slotman, Ben J.
    Ramella, Sara
    Poettgen, Christoph
    Peeters, Stephanie T. H.
    Nestle, Ursula
    McDonald, Fiona
    Le Pechoux, Cecile
    Dziadziuszko, Rafal
    Belderbos, Jose
    Ricardi, Umberto
    Manapov, Farkhad
    Lievens, Yolande
    Geets, Xavier
    Dieckmann, Karin
    Guckenberger, Matthias
    Andratschke, Nicolaus
    Suveg, Krisztian
    Putora, Paul M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 154 : 269 - 273
  • [34] Proactive Management of Potential Gastrointestinal Adverse Reactions with Ceritinib in Patients with Advanced ALK plus NSCLC
    Schaefer, Eric
    Power, Margaret
    Baik, Christina
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S530 - S530
  • [35] Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
    Wakelee, H.
    Sanborn, R.
    Nieva, J.
    Waqar, S.
    Brzezniak, C.
    Bauman, J.
    Neal, J.
    Dukart, G.
    Tan, F.
    Harrow, K.
    Liang, C.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1826 - S1826
  • [36] Diverse Characteristics of ALK plus NSCLC Patients in the United States
    Bendaly, Edmond
    Sasane, Medha
    Zhang, Jie
    Swallow, Elyse
    Macalalad, Alexander R.
    Patel, Dony
    Kageleiry, Andrew
    Galebach, Philip
    Kercheval, Jacquelyn
    Stein, Karen
    Guerin, Annie
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S376
  • [37] Role of QoL in Treatment Decisions for Patients with ALK plus NSCLC
    Law, H.
    King, J. C.
    Lin, H. M.
    Curran, E.
    Wiens, J.
    Cruz, L.
    Blender, J.
    Venanzi, E. S.
    Schenk, E.
    Lin, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S113 - S114
  • [38] Experience from the ASCEND-1 trial: Ceritinib in patients (Pts) with ALK-rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) and brain metastases
    Thomas, M.
    Schuler, M.
    Potzner, M.
    Szczudlo, T.
    Sutradhar, S.
    Yovine, A.
    Wolf, J.
    Oncology Research and Treatment, 2015, 38 : 270 - 270
  • [39] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [40] Analysis of resistance mechanisms to ALK kinase inhibitors in ALK plus NSCLC patients.
    Doebele, Robert Charles
    Aisner, Dara L.
    Le, Anh T.
    Berge, Eamon M.
    Pilling, Amanda B.
    Kutateladze, Tatiana G.
    Weickhardt, Andrew James
    Franklin, Wilbur A.
    Varella-Garcia, Marileila
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345